KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Current Liabilities: 2017-2024

Historic Total Current Liabilities for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $2.2 billion.

  • Moderna's Total Current Liabilities fell 23.63% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 23.63%. This contributed to the annual value of $2.2 billion for FY2024, which is 26.83% down from last year.
  • According to the latest figures from FY2024, Moderna's Total Current Liabilities is $2.2 billion, which was down 26.83% from $3.0 billion recorded in FY2023.
  • Over the past 5 years, Moderna's Total Current Liabilities peaked at $9.1 billion during FY2021, and registered a low of $2.2 billion during FY2024.
  • In the last 3 years, Moderna's Total Current Liabilities had a median value of $3.0 billion in 2023 and averaged $3.4 billion.
  • Per our database at Business Quant, Moderna's Total Current Liabilities surged by 2,966.76% in 2020 and then tumbled by 46.07% in 2022.
  • Over the past 5 years, Moderna's Total Current Liabilities (Yearly) stood at $4.4 billion in 2020, then spiked by 107.97% to $9.1 billion in 2021, then slumped by 46.07% to $4.9 billion in 2022, then tumbled by 38.76% to $3.0 billion in 2023, then declined by 26.83% to $2.2 billion in 2024.